solutions
HEOR
Whether a new therapeutic agent is reimbursed depends not only on its clinical efficacy, but also on robust health economic evidence. It is precisely this evidence that our HEOR Solution generates: robust economic modelling, combined with reliable healthcare data, captures budgetary impacts, cost-benefit ratios and patient-relevant benefits – in line with established HEOR standards and national and European HTA procedures. This creates methodologically sound decision-making foundations that demonstrate the economic value of medical innovations – to HTA bodies, payers and the scientific community.
An overview of our services
Cost-effectiveness, real-world evidence, health technology assessment, regulatory decision-making
our use cases
We have modelled the multi-year budgetary implications for the funding bodies following the introduction of a medicinal product for atopic dermatitis.
For selected cancer indications, we have quantified the direct and indirect burden of disease on the German healthcare system.
For the German market, we have compared the costs of various HPV screening algorithms and quantified the potential savings for statutory health insurance schemes.
We used a population-based Markov model to calculate the cost-effectiveness of an innovative product compared with standard therapy.
We have carried out a model-based assessment of the long-term clinical and economic benefits of a patient monitoring system for heart failure.
Using a population-based SIR model, we simulated the course of a flu outbreak and the effect of different vaccination rates.
Using retrospective study data, we have evaluated a new combination therapy under real-world conditions.
We have used a scenario-based approach to quantify the business and healthcare implications of a ban on the telemedical prescription of medical cannabis.